MXPA01008465A - Biotinylated-chemokine antibody complexes. - Google Patents

Biotinylated-chemokine antibody complexes.

Info

Publication number
MXPA01008465A
MXPA01008465A MXPA01008465A MXPA01008465A MXPA01008465A MX PA01008465 A MXPA01008465 A MX PA01008465A MX PA01008465 A MXPA01008465 A MX PA01008465A MX PA01008465 A MXPA01008465 A MX PA01008465A MX PA01008465 A MXPA01008465 A MX PA01008465A
Authority
MX
Mexico
Prior art keywords
biotinylated
complexes
biotin
antibody complexes
chemokine antibody
Prior art date
Application number
MXPA01008465A
Other languages
Spanish (es)
Inventor
Walter Newman
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MXPA01008465A publication Critical patent/MXPA01008465A/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Biotinylated pharmacologically active agents and complexes containing same are disclosed. In particular, biotinylated-chemokines are described. The complexes further include an anti-biotin antibody that selectively binds to biotin. The complex can be dissociated by contact with free biotin. The complexes are particularly useful for enhancing an immune response to tumor cells and virus-infected cells, in vivo or in vitro.
MXPA01008465A 1999-02-22 2000-02-18 Biotinylated-chemokine antibody complexes. MXPA01008465A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12100699P 1999-02-22 1999-02-22
PCT/US2000/004312 WO2000050088A2 (en) 1999-02-22 2000-02-18 Biotinylated-chemokine antibody complexes

Publications (1)

Publication Number Publication Date
MXPA01008465A true MXPA01008465A (en) 2003-06-06

Family

ID=22393879

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01008465A MXPA01008465A (en) 1999-02-22 2000-02-18 Biotinylated-chemokine antibody complexes.

Country Status (6)

Country Link
EP (1) EP1154799A2 (en)
JP (1) JP2002537362A (en)
AU (1) AU3370000A (en)
CA (1) CA2371849A1 (en)
MX (1) MXPA01008465A (en)
WO (1) WO2000050088A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877177B2 (en) 2008-09-10 2014-11-04 Ith Immune Therapy Holdings Ab Chemokine containing apheresis column and methods of use
JP2014502607A (en) * 2011-01-03 2014-02-03 エフ．ホフマン−ラ ロシュ アーゲー Pharmaceutical composition of complex of digoxigenin conjugated with anti-DIG antibody and peptide
ES2664836T3 (en) 2011-06-13 2018-04-23 Tla Targeted Immunotherapies Ab Multiple sclerosis treatment
EP2718313B1 (en) * 2011-06-13 2017-05-17 TLA Targeted Immunotherapies AB Treating respiratory conditions
ES2801901T3 (en) 2011-06-13 2021-01-14 Tla Targeted Immunotherapies Ab Treatment of conditions associated with metabolic syndrome
WO2012172337A2 (en) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating cardiovascular disease
WO2012172336A2 (en) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating inflammatory skin diseases
US9726666B2 (en) 2011-06-13 2017-08-08 Tla Targeted Immunotherapies Ab Diagnosing and treating inflammatory diseases
WO2012172345A2 (en) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating conditions associated with allergy
EP2718310B1 (en) 2011-06-13 2017-08-23 TLA Targeted Immunotherapies AB Treating mental disorders
EP3176583B1 (en) 2011-06-13 2019-09-11 TLA Targeted Immunotherapies AB Diagnosing and treating inflammatory bowel disease and irritable bowel syndrome
WO2012172343A2 (en) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating primary sclerosing cholangitis
CN103857421B (en) 2011-06-13 2017-09-22 Tla指标免疫疗法公司 The method for the treatment of cancer and the binding reagents used wherein
WO2012172339A2 (en) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating inflammatory arthritis
WO2012172344A2 (en) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating conditions associated with sepsis
CN107973856B (en) 2012-07-04 2021-11-23 弗·哈夫曼-拉罗切有限公司 Covalently linked antigen-antibody conjugates
BR112014030843A2 (en) 2012-07-04 2019-10-15 Hoffmann La Roche anti-theophylline antibody, pharmaceutical formulation and use of the antibody
CA2872192A1 (en) * 2012-07-04 2014-01-09 F. Hoffmann-La Roche Ag Anti-biotin antibodies and methods of use
KR102051433B1 (en) * 2013-08-27 2020-01-08 (주)네오팜 A composition and external application for acceleration of muscle differentiation and improving of muscle mass
CN105873616B (en) 2014-01-03 2020-06-05 豪夫迈·罗氏有限公司 Covalently linked polypeptide toxin-antibody conjugates
WO2015101586A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
CN105873615B (en) 2014-01-03 2020-12-25 豪夫迈·罗氏有限公司 Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
CA2947504A1 (en) 2014-06-26 2015-12-30 F. Hoffmann-La Roche Ag Anti-brdu antibodies and methods of use
KR102448439B1 (en) * 2016-12-27 2022-09-27 에프. 호프만-라 로슈 아게 Novel biotin-specific monoclonal antibodies and uses thereof
EP3562842A1 (en) * 2016-12-27 2019-11-06 H. Hoffnabb-La Roche Ag Novel biotin-specific monoclonal antibody and use thereof
BR112019010915A2 (en) * 2016-12-27 2019-10-01 Hoffmann La Roche monoclonal antibody, methods for measuring an analyte in a sample and for producing an antibody, use of an antibody, immunoassay and immunogen test kit
CN111171154B (en) * 2020-02-25 2021-05-11 杭州百凌生物科技有限公司 Anti-biotin antibody and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1248685B (en) * 1990-06-04 1995-01-26 Tecnogen Scpa PROCEDURE FOR THE IDENTIFICATION OF POLYNUCLEOTIDIC SEQUENCES AND RELATED DEVICE
US6579696B1 (en) * 1992-12-21 2003-06-17 Promega Corporation Polymyxin B conjugates
WO1998033914A1 (en) * 1997-01-31 1998-08-06 University Of Rochester Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
WO2000012554A1 (en) * 1998-08-28 2000-03-09 Commissariat A L'energie Atomique Method for marked chemokine synthesis, marked chemokine and analysis kit
CA2363067C (en) * 1999-01-12 2012-03-20 David J. Grainger Compounds and methods to inhibit or augment an inflammatory response

Also Published As

Publication number Publication date
CA2371849A1 (en) 2000-08-31
WO2000050088A3 (en) 2000-12-21
AU3370000A (en) 2000-09-14
JP2002537362A (en) 2002-11-05
WO2000050088A2 (en) 2000-08-31
EP1154799A2 (en) 2001-11-21

Similar Documents

Publication Publication Date Title
MXPA01008465A (en) Biotinylated-chemokine antibody complexes.
HK1033582A1 (en) Antibodies to death receptor 4 (dr4) and uses thereof
TR200003513T2 (en) Pirolo [2,3d] Pyrimidine compositions and uses
MXPA02001726A (en) Fuel cell and bipolar plate for use with same.
HK1086750A1 (en) Pharmaceutical composition for inducing an immune response in a human or animal
DK1082410T3 (en) Human CD45 and / or fibroblast mesenchymal stem cells
TR200102711T2 (en) Anticonvulsant derivatives for use in the treatment of crisis headaches
CA2359440A1 (en) Phenylphenanthridines with pde-iv inhibiting activity
DE69906977D1 (en) NUCLEIC ACID COMPLEXES ENCLOSED IN LIPOSOMES
MY109880A (en) Substituted biphenylpyridones
LV11429A (en) Tricyclopiazamacrocyclophosphonates for complexes and derivatives for use as contrast media
AU2002364935A1 (en) Enhancement of immune responses by 4-1bb-binding agents
BRPI0012196B8 (en) industrialized article
IL146448A0 (en) Dr4 antibodies and uses thereof
SI0998460T1 (en) Novel tetrazole derivatives
ITRM920411A1 (en) PROCEDURE TO PRODUCE GLYCOSYLTRANSFERASE, HYBRID YEAR CARRIER IN ITS EMPLOYMENT AND YEAST STOCK TRANSFORMED WITH THE USE OF HYBRID VECTOR.
DE69920949D1 (en) ASCOMYCIN-CONTAINING TOPICAL PREPARATIONS
AU3365499A (en) Isolated multimeric complexes useful in analysis of t cells, peptides useful in making the complexes, and uses thereof
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
AU2002217721A1 (en) Viral vector for gene therapy
MX9602557A (en) Proteins from mammalian liver and their use in oncology.
ATE265336T1 (en) CARRIER
ES2181461T3 (en) USE OF NEW INDUCTIVE AGENTS OF CELL DEATH IN SYNERGY WITH INTERFERONS.
WO2000066731A3 (en) Recombinant laminin 5
MX9708697A (en) Method of diagnosing prostate cancer.